Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 509-535

  Pfeifer, Nathan D ^a   Hardwick, Rhiannon N ^b   Brouwer, Kim L R ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Drug drug interactions; Intracellular unbound concentration; Sandwich cultured hepatocytes; Transporter multiplicity; Transporter regulation; Transporter trafficking

Indexed keywords

CARRIER PROTEIN; XENOBIOTIC AGENT;

ENVIRONMENTAL EXPOSURE; ENZYME SUBSTRATE; FUNCTIONAL DISEASE; GENETIC POLYMORPHISM; HEPATITIS C VIRUS; HUMAN; INHIBITION KINETICS; INTRAHEPATIC CHOLESTASIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; METABOLITE; MOLECULAR DYNAMICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS.; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; BILE; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CELL MEMBRANE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; LIVER; XENOBIOTICS;

EID: 84891885073     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-140021     Document Type: Review

References (198)

1. Esteller A. 2008. Physiology of bile secretion. World J. Gastroenterol. 14:5641-49
2. Stieger B. 2010. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab. Rev. 42:437-45
3. Kubitz R, Droge C, Stindt J, Weissenberger K, Haussinger D. 2012. The bile salt export pump (BSEP) in health and disease. Clin. Res. Hepatol. Gastroenterol. 36:536-53
4. +-organic cation antiporters. Biochem. Pharmacol. 74:359-71
5. Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, Krajcsi P. 2010. ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metab. Rev. 42:402-36
6. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KLR. 2006. Integration of hepatic drug transporters and phase II metabolizing enzymes:mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci. 27:447-86
7. Pauli-Magnus C, Meier PJ. 2006. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44:778-87
8. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, et al. 2009. ABCG2: a perspective. Adv. Drug Deliv. Rev. 61:3-13
9. Koshiba S, An R, Saito H, Wakabayashi K, Tamura A, Ishikawa T. 2008. Human ABC transporters ABCG2 (BCRP) and ABCG4. Xenobiotica 38:863-88
10. Robey RW, Ierano C, Zhan Z, Bates SE. 2011. The challenge of exploiting ABCG2 in the clinic. Curr. Pharm. Biotechnol. 12:595-608
11. Cascorbi I. 2011. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb. Exp. Pharmacol. 201:261-83
12. +/organic cation antiporter multidrug and toxin extrusion (MATE). Mol. Pharmacol. 71:1487-93
13. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. 2005. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. USA 102:17923-28
14. +/organic cation antiporterMATE1. Pharm. Res. 23:1696-701
15. Chandra P, Brouwer KLR. 2004. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21:719-35
16. Fagerholm U. 2008. Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation. J. Pharm. Pharmacol. 60:535-42
17. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. 2002. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 41:751-90
18. Stieger B, Meier PJ. 2011. Pharmacogenetics of drug transporters in the enterohepatic circulation. Pharmacogenomics 12:611-31
19. Cremers S, Schoemaker R, Scholten E, den Hartigh J, Konig-Quartel J, et al. 2005. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br. J. Clin. Pharmacol. 60:249-56
20. Rausl D, Fotaki N, Zanoski R, Vertzoni M, Cetina-Cizmek B, et al. 2006. Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration. J. Pharm. Pharmacol. 58:827-36
21. Duggan DE, Hooke KF, Noll RM, Kwan KC. 1975. Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem. Pharmacol. 24:1749-54
22. Kouzuki H, Suzuki H, Sugiyama Y. 2000. Pharmacokinetic study of the hepatobiliary transport of indomethacin. Pharm. Res. 17:432-38
23. Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, et al. 2011. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br. J. Clin. Pharmacol. 72:294-305
24. Pollack GM, Brouwer KLR. 1991. Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat. J. Pharmacokinet. Biopharm. 19:189-225
25. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, et al. 1995. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol. 6:141-51
26. Chiang JY. 2009. Bile acids: regulation of synthesis. J. Lipid Res. 50:1955-66
27. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. 2011. Drug-induced cholestasis. Hepatology 53:1377-87
28. de Lannoy IA, Barker F III, Pang KS. 1993. Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver. J. Pharmacokinet. Biopharm. 21:395-422
29. Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, Brouwer KLR. 2008. Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab. Dispos. 36:911-15
30. Iusuf D, van de Steeg E, Schinkel AH. 2012. Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification. Clin. Pharmacol. Ther. 92:559-62
31. Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken MJ, et al. 2007. Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab. Dispos. 35:1963-69
32. Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ. 2011. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 39:2395-402
33. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, et al. 2008. Substrates and inhibitors of humanmultidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 15:1981-2039
34. -/- mice. J. Pharmacol. Exp. Ther. 319:1485-91
35. Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, et al. 2006. Upregulation of a basolateral FXRdependent bile acid efflux transporterOSTα-OSTβin cholestasis in humans and rodents. Am. J. Physiol. Gastrointest. Liver Physiol. 290:G1124-30
36. Ballatori N, Li N, Fang F, Boyer JL, Christian WV, Hammond CL. 2009. OSTα-OSTβ: a key membrane transporter of bile acids and conjugated steroids. Front. Biosci. 14:2829-44
37. Ballatori N, Christian WV, Wheeler SG, Hammond CL. 2013. The heteromeric organic solute transporter, OSTα-OSTβ/SLC51: a transporter for steroid-derived molecules. Mol. Aspects Med. 34:683-92
38. Ballatori N, Christian WV, Lee JY, Dawson PA, Soroka CJ, et al. 2005. OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42:1270-79
39. Li L, Meier PJ, Ballatori N. 2000. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol. Pharmacol. 58:335-40
40. Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N. 2007. Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am. J. Physiol. Gastrointest. Liver Physiol. 293:G271-78
41. Tang W. 2007. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 3:407-20
42. Shaw LM, Figurski M, Milone MC, Trofe J, Bloom RD. 2007. Therapeutic drug monitoring of mycophenolic acid. Clin. J. Am. Soc. Nephrol. 2:1062-72
43. Kruh GD, Belinsky MG. 2003. The MRP family of drug efflux pumps. Oncogene 22:7537-52
44. Ayrton A, Morgan P. 2001. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-97
45. Hoffmann U, Kroemer HK. 2004. The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab. Rev. 36:669-701
46. Konig J, Nies AT, Cui Y, Leier I, Keppler D. 1999. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461:377-94
47. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, et al. 1997. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031-35
48. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, et al. 1997. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer 76:1181-83
49. Ho RH, Kim RB. 2005. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78:260-77
50. Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, et al. 2006. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90:451-59
51. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, et al. 2001. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69:223-31
52. Karthik SV, Casson D. 2005. Erythromycin-associated cholestatic hepatitis and liver dysfunction in children: the British experience. J. Clin. Gastroenterol. 39:743-44
53. Dawson S, Stahl S, Paul N, Barber J, Kenna JG. 2012. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 40:130-38
54. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, et al. 2010. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 118:485-500
55. Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, et al. 2012. Inhibition of the hepatic basolateral bile acid transporterMRP4 predicts cholestatic drug-induced liver injury (DILI). Hepatology 56(6):1530A (Abstr.)
56. Alvarez AI, Real R, Perez M, Mendoza G, Prieto JG, Merino G. 2010. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J. Pharm. Sci. 99:598-617
57. Gandhi YA, Morris ME. 2009. Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2). AAPS J. 11:541-52
58. Natarajan K, Xie Y, Baer MR, Ross DD. 2012. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem. Pharmacol. 83:1084-103
59. Broccatelli F, Carosati E, Neri A, Frosini M, Goracci L, et al. 2011. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J. Med. Chem. 54:1740-51
60. Sakurai A, Kurata A, Onishi Y, Hirano H, Ishikawa T. 2007. Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump. Expert Opin. Drug Saf. 6:71-86
61. Ozawa N, Shimizu T, Morita R, Yokono Y, Ochiai T, et al. 2004. Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm. Res. 21:2133-34
62. Saier MH Jr, Yen MR, Noto K, Tamang DG, Elkan C. 2009. The Transporter Classification Database: recent advances. Nucleic Acids Res. 37:D274-78
63. Ren Q, Chen K, Paulsen IT. 2007. Transport DB: a comprehensive database resource for cytoplasmic membrane transport systems and outer membrane channels. Nucleic Acids Res. 35:D274-79
64. Yee SW, Chen L, Giacomini KM. 2010. Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics 11:475-79
65. Sedykh A, Fourches D, Duan J, Hucke O, Garneau M, et al. 2012. Human Intestinal Transporter Database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm. Res. 30:996-1007
66. Kindla J, Muller F, Mieth M, Fromm MF, Konig J. 2011. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab. Dispos. 39:1047-53
67. Vallejo M, Briz O, Serrano MA, Monte MJ, Marin JJ. 2006. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J. Hepatol. 44:1150-57
68. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. 2000. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-30
69. Gertz M, Cartwright CM, Hobbs MJ, Kenworthy KE, Rowland M, et al. 2013. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential. Pharm. Res. 30:761-80
70. Shitara Y, Nagamatsu Y, Wada S, Sugiyama Y, Horie T. 2009. Long-lasting inhibition of the transportermediated hepatic uptake of sulfobromophthalein by cyclosporinA in rats. Drug Metab. Dispos. 37:1172-78
71. Sterz K, Mollmann L, Jacobs A, Baumert D, Wiese M. 2009. Activators of P-glycoprotein: structureactivity relationships and investigation of their mode of action. Chem Med Chem 4:1897-911
72. Heredi-Szabo K, Jemnitz K, Kis E, Ioja E, Janossy J, et al. 2009. Potentiation of MRP2/Mrp2-mediated estradiol-17β-glucuronide transport by drugs-a concise review. Chem. Biodivers. 6:1970-74
73. Kauffmann HM, Keppler D, Kartenbeck J, Schrenk D. 1997. Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Hepatology 26:980-85
74. Perloff MD, Von Moltke LL, Marchand JE, Greenblatt DJ. 2001. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J. Pharm. Sci. 90:1829-37
75. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. 2011. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54:20-27
76. Suzuki H, Sugiyama Y. 2002. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. 54:1311-31
77. Staud F, Pavek P. 2005. Breast cancer resistance protein (BCRP/ABCG2). Int. J. Biochem. Cell Biol. 37:720-25
78. Cascorbi I, Haenisch S. 2010. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol. Biol. 596:95-121
79. Keitel V, Kartenbeck J, Nies AT, Spring H, Brom M, Keppler D. 2000. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 32:1317-28
80. Keitel V, Nies AT, Brom M, Hummel-Eisenbeiss J, Spring H, Keppler D. 2003. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am. J. Physiol. Gastrointest. Liver Physiol. 284:G165-74
81. Sookoian S, Castano G, Gianotti TF, Gemma C, Pirola CJ. 2009. Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J. Nutr. Biochem. 20:765-70
82. Elens L, Tyteca D, Panin N, Courtoy P, Lison D, et al. 2011. Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet. Genomics 21:884-93
83. Choi JH, Ahn BM, Yi J, Lee JH, Nam SW, et al. 2007. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics 17:403-15
84. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. 2011. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 11:25-34
85. Ansari M, Sauty G, Labuda M, Gagne V, Laverdiere C, et al. 2009. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 114:1383-86
86. Bruggemann M, Trautmann H, Hoelzer D, Kneba M, Gokbuget N, Raff T. 2009. Multidrug resistance-associated protein 4 (MRP4) gene polymorphisms and treatment response in adult acute lymphoblastic leukemia. Blood 114:5400-1; author reply 5401-2
87. Wada M. 2006. Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response. Cancer Lett. 234:40-50
88. Elens L, Capron A, Kerckhove VV, Lerut J, Mourad M, et al. 2007. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet. Genomics 17:873-83
89. Ieiri I. 2012. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab. Pharmacokinet. 27:85-105
90. Mizuarai S, Aozasa N, Kotani H. 2004. Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int. J. Cancer 109:238-46
91. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, et al. 2003. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol. 38:717-27
92. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, et al. 2001. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33:633-46
93. Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA. 2003. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J. Pathol. 200:553-60
94. Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, et al. 2007. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int. 27:920-29
95. Gradhand U, Lang T, Schaeffeler E, Glaeser H, Tegude H, et al. 2008. Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J. 8:42-52
96. Hanada K, Nakai K, Tanaka H, Suzuki F, Kumada H, et al. 2012. Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab. Pharmacokinet. 27:301-6
97. Kurzawski M, Dziedziejko V, Post M, Wojcicki M, Urasinska E, et al. 2012. Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1. Pharmacol. Rep. 64:927-39
98. Ogasawara K, Terada T, Katsura T, Hatano E, Ikai I, et al. 2010. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab. Pharmacokinet. 25:190-99
99. Borel F, Han R, Visser A, Petry H, van Deventer SJ, et al. 2012. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 55:821-32
100. Bonin S, Pascolo L, Croce LS, Stanta G, Tiribelli C. 2002. Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue, and liver diseases. Mol. Med. 8:318-25
101. Keitel V, Burdelski M, Warskulat U, Kuhlkamp T, Keppler D, et al. 2005. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 41:1160-72
102. Kipp H, Arias IM. 2002. Trafficking of canalicular ABC transporters in hepatocytes. Annu. Rev. Physiol. 64:595-608
103. Wakabayashi Y, Kipp H, Arias IM. 2006. Transporters on demand: intracellular reservoirs and cycling of bile canalicular ABC transporters. J. Biol. Chem. 281:27669-73
104. Ji B, Ito K, Sekine S, Tajima A, Horie T. 2004. Ethacrynic-acid-induced glutathione depletion and oxidative stress in normal and Mrp2-deficient rat liver. Free Radic. Biol. Med. 37:1718-29
105. Mottino AD, Crocenzi FA, Pozzi EJ, Veggi LM, Roma MG, Vore M. 2005. Role of microtubules in estradiol-17β-D-glucuronide-induced alteration of canalicular Mrp2 localization and activity. Am. J. Physiol. Gastrointest. Liver Physiol. 288:G327-36
106. Sekine S, Mitsuki K, Ito K, Kugioka S, Horie T. 2012. Sustained intrahepatic glutathione depletion causes proteasomal degradation ofmultidrug resistance-associated protein 2 in rat liver. Biochim. Biophys. Acta 1822:980-87
107. Kojima H, Nies AT, Konig J, Hagmann W, Spring H, et al. 2003. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J. Hepatol. 39:693-702
108. Kojima H, Sakurai S, Uemura M, Kitamura K, Kanno H, et al. 2008. Disturbed colocalization of multidrug resistance protein 2 and radixin in human cholestatic liver diseases. J. Gastroenterol. Hepatol. 23:e120-28
109. Kipp H, Arias IM. 2000. Intracellular trafficking and regulation of canalicular ATP-binding cassette transporters. Semin. Liver Dis. 20:339-51
110. Kipp H, Pichetshote N, Arias IM. 2001. Transporters on demand: intrahepatic pools of canalicular ATP binding cassette transporters in rat liver. J. Biol. Chem. 276:7218-24
111. Wojtal KA, de Vries E, Hoekstra D, van Ijzendoorn SC. 2006. Efficient trafficking of MDR1/Pglycoprotein to apical canalicular plasma membranes in HepG2 cells requires PKA-RIIα anchoring and glucosylceramide. Mol. Biol. Cell 17:3638-50
112. Fu D, van Dam EM, Brymora A, Duggin IG, Robinson PJ, Roufogalis BD. 2007. The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein. Biochim. Biophys. Acta 1773:1062-72
113. Ferrandiz-Huertas C, Fernandez-Carvajal A, Ferrer-Montiel A. 2011. Rab4 interacts with the human P-glycoprotein and modulates its surface expression in multidrug resistant K562 cells. Int. J. Cancer 128:192-205
114. Sekine S, Ito K, Saeki J, Horie T. 2011. Interaction of Mrp2 with radixin causes reversible canalicular Mrp2 localization induced by intracellular redox status. Biochim. Biophys. Acta 1812:1427-34
115. 2+-dependent protein kinase C isoforms are critical to estradiol 17β-D-glucuronide-induced cholestasis in the rat. Hepatology 48:1885-95
116. Rost D, Kloeters-Plachky P, Stiehl A. 2008. Retrieval of the rat canalicular conjugate export pumpMrp2 is associated with a rearrangement of actin filaments and radixin in bile salt-induced cholestasis. Eur. J. Med. Res. 13:314-18
117. Boaglio AC, Zucchetti AE, Sanchez Pozzi EJ, Pellegrino JM, Ochoa JE, et al. 2010. Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17β-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology 52:1465-76
118. Boaglio AC, Zucchetti AE, Toledo FD, Barosso IR, Sanchez Pozzi EJ, et al. 2012. ERK1/2 and p38 MAPKs are complementarily involved in estradiol 17β-D-glucuronide-induced cholestasis: crosstalk with cPKC and PI3K. PLoS ONE 7:e49255
119. Mottino AD, Cao J, Veggi LM, Crocenzi F, Roma MG, Vore M. 2002. Altered localization and activity of canalicular Mrp2 in estradiol-17β-D- glucuronide-induced cholestasis. Hepatology 35:1409-19
120. Sekine S, Ito K, Horie T. 2008. Canalicular Mrp2 localization is reversibly regulated by the intracellular redox status. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G1035-41
121. Schonhoff CM, Gillin H, Webster CR, Anwer MS. 2008. Protein kinase Cδ mediates cyclic adenosine monophosphate-stimulated translocation of sodium taurocholate cotransporting polypeptide and multidrug resistant associated protein 2 in rat hepatocytes. Hepatology 47:1309-16
122. Mohrmann K, van Eijndhoven MA, Schinkel AH, Schellens JH. 2005. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother. Pharmacol. 56:344-50
123. Nakagawa H, Wakabayashi-Nakao K, Tamura A, Toyoda Y, Koshiba S, Ishikawa T. 2009. Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATPbinding cassette transporter ABCG2. FEBS J. 276:7237-52
124. Draheim V, Reichel A, Weitschies W, Moenning U. 2010. N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. Eur. J. Pharm. Sci. 41:201-9
125. Fernandez SB, Hollo Z, Kern A, Bakos E, Fischer PA, et al. 2002. Role of the N-terminal transmembrane region of the multidrug resistance protein MRP2 in routing to the apical membrane in MDCKII cells. J. Biol. Chem. 277:31048-55
126. Zhang P, Tian X, Chandra P, Brouwer KLR. 2005. Role of glycosylation in trafficking of Mrp2 in sandwich-cultured rat hepatocytes. Mol. Pharmacol. 67:1334-41
127. + exchanger regulatory factor 1 increases expression and function of multidrug resistance protein 4. Cancer Res. 68:4802-9
128. Hayashi H, Naoi S, Nakagawa T, Nishikawa T, Fukuda H, et al. 2012. Sorting nexin 27 interacts with multidrug resistance-associated protein 4 (MRP4) and mediates internalization of MRP4. J. Biol. Chem. 287:15054-65
129. Chandra P, Zhang P, Brouwer KLR. 2005. Short-term regulation of multidrug resistance-associated protein 3 in rat and human hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 288:G1252-58
130. Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, Brouwer KLR. 2009. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab. Dispos. 37:386-90
131. Vlaming ML, van Esch A, Pala Z, Wagenaar E, van de Wetering K, et al. 2009. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol. Cancer Ther. 8:3350-59
132. Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, et al. 2009. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin. Cancer Res. 15:3084-93
133. Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, et al. 2008. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin. Cancer Res. 14:8152-60
134. de Waart DR, Vlaming ML, Kunne C, Schinkel AH, Oude Elferink RPJ. 2009. Complex pharmacokinetic behavior of ezetimibe depends on Abcc2, Abcc3, and Abcg2. Drug Metab. Dispos. 37:1698-702
135. Lee JK, Leslie EM, Zamek-Gliszczynski MJ, Brouwer KLR. 2008. Modulation of trabectedin (ET-743) hepatobiliary disposition bymultidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicol. Appl. Pharmacol. 228:17-23
136. van Waterschoot RA, Eman RM, Wagenaar E, van der Kruijssen CM, Rosing H, et al. 2009. ABCC2, ABCC3, and ABCB1, but not CYP3A, protect against trabectedin-mediated hepatotoxicity. Clin. Cancer Res. 15:7616-23
137. Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, et al. 2008. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol. Pharmacol. 73:1474-83
138. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. 2008. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 36:663-69
139. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27:866-71
140. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KLR. 2004. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J. Pharmacol. Exp. Ther. 311:1203-10
141. Kitamura S, Maeda K, Wang Y, Sugiyama Y. 2008. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos. 36:2014-23
142. Hobbs M, Parker C, Birch H, Kenworthy K. 2012. Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model. Xenobiotica 42:327-38
143. Ward ES, Pollack GM, Brouwer KLR. 2000. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: Can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? Drug Metab. Dispos. 28:1433-39
144. 99mtechnetiummebrofenin disposition in humans: a semi-PBPK modeling and in vitro approach to predict transportermediated DDIs. CPT: Pharmacomet. Syst. Pharmacol. 2:e20
145. Lam JL, Okochi H, Huang Y, Benet LZ. 2006. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos. 34:1336-44
146. Fan J, Maeng HJ, Pang KS. 2010. Interplay of transporters and enzymes in the Caco-2 cell monolayer: I. Effect of altered apical secretion. Biopharm. Drug Dispos. 31:215-27
147. Pang KS, Maeng HJ, Fan J. 2009. Interplay of transporters and enzymes in drug and metabolite processing. Mol. Pharm. 6:1734-55
148. Lee JK, Marion TL, Abe K, Lim C, Pollock GM, Brouwer KLR. 2010. Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation. J. Pharmacol. Exp. Ther. 332:26-34
149. Hennessy M, Spiers JP. 2007. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol. Res. 55:1-15
150. Stein WD. 1997. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol. Rev. 77:545-90
151. Korzekwa KR, Nagar S, Tucker J, Weiskircher EA, Bhoopathy S, Hidalgo IJ. 2012. Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab. Dispos. 40:865-76
152. Ihrke G, Martin GV, Shanks MR, Schrader M, Schroer TA, Hubbard AL. 1998. Apical plasma membrane proteins and endolyn-78 travel through a subapical compartment in polarizedWIF-B hepatocytes. J. Cell Biol. 141:115-33
153. Kipp H, Arias IM. 2000. Newly synthesized canalicular ABC transporters are directly targeted from the Golgi to the hepatocyte apical domain in rat liver. J. Biol. Chem. 275:15917-25
154. Van IJzendoorn SCD, Maier O, Van Der Wouden JM, Hoekstra D. 2000. The subapical compartment and its role in intracellular trafficking and cell polarity. J. Cell. Physiol. 184:151-60
155. Wustner D, Mukherjee S, Maxfield FR, Muller P, Herrmann A. 2001. Vesicular and nonvesicular transport of phosphatidylcholine in polarized HepG2 cells. Traffic 2:277-96
156. Nies AT, Cantz T, Brom M, Leier I, Keppler D. 1998. Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B. Hepatology 28:1332-40
157. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, et al. 1995. Expression of multidrug resistanceassociated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 55:5342-47
158. Boyer JL, Soroka CJ. 1995. Vesicle targeting to the apical domain regulates bile excretory function in isolated rat hepatocyte couplets. Gastroenterology 109:1600-11
159. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KLR, et al. 2010. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9:215-36
160. Brouwer KLR, Keppler D, Hoffmaster KA, Bow DAJ, Cheng Y, et al. 2013. In vitro methods to support transporter evaluation in drug discovery and development. Clin. Pharmacol. Ther. 94:95-112
161. Swift B, Pfeifer ND, Brouwer KLR. 2010. Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab. Rev. 42:446-71
162. Oshio C, Phillips MJ. 1981. Contractility of bile canaliculi: implications for liver function. Science 212:1041-42
163. Phillips MJ, Oshio C, Miyairi M, Katz H, Smith CR. 1982. A study of bile canalicular contractions in isolated hepatocytes. Hepatology 2:763-68
164. Boyer JL, Gautam A, Graf J. 1988. Mechanisms of bile secretion: insights from the isolated rat hepatocyte couplet. Semin. Liver Dis. 8:308-16
165. 2,5] enkephalin. Drug Metab. Dispos. 33:287-93
166. 2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J. Pharmacol. Exp. Ther. 289:1592-99
167. Pfeifer ND, Yang K, Brouwer KLR. 2013. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition: I. Characterization of basolateral vs. biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J. Pharmacol. Exp. Ther. In press. doi: 10.1124/jpet.113.207472
168. Yang K, Brouwer KLR. 2012. Pharmacokinetic modeling and simulation study to predict the impact of troglitazone (TGZ) on the hepatobiliary disposition of taurocholate (TC) in rat sandwich-cultured hepatocytes (SCH). Presented at AAPS Annu. Meet., Oct. 14-18, Chicago, IL (Poster M1324)
169. Brouwer KLR, Thurman RG. 1996. Isolated perfused liver. Pharm. Biotechnol. 8:161-92
170. Akita H, Suzuki H, Sugiyama Y. 2001. Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver. Pharm. Res. 18:1119-25
171. Chandra P, Johnson BM, Zhang P, Pollack GM, Brouwer KLR. 2005. Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver. Drug Metab. Dispos. 33:1238-43
172. Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW. 2012. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metab. Dispos. 40:1825-33
173. Yue W, Abe K, Brouwer KLR. 2009. Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion. Mol. Pharm. 6:134-43
174. Ohtsuki S, Uchida Y, Kubo Y, Terasaki T. 2011. Quantitative targeted absolute proteomics-basedADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J. Pharm. Sci. 100:3547-59
175. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF. 2012. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab. Dispos. 40:1164-69
176. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. 2011. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J. Pharmacol. Exp. Ther. 339:579-88
177. Shawahna R, Uchida Y, Decleves X, Ohtsuki S, Yousif S, et al. 2011. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm. 8:1332-41
178. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, et al. 2011. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 117:333-45
179. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, et al. 2008. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneousLC/MS/MSmethod combined with novel in-silico peptide selection criteria. Pharm. Res. 25:1469-83
180. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, et al. 2012. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol. Pharm. 9:3535-42
181. Li N, Bi YA, Duignan DB, Lai Y. 2009. Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol. Pharm. 6:1180-89
182. Li N, Palandra J, Nemirovskiy OV, Lai Y. 2009. LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species. Anal. Chem. 81:2251-59
183. Li N, Zhang Y, Hua F, Lai Y. 2009. Absolute difference of hepatobiliary transportermultidrug resistanceassociated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab. Dispos. 37:66-73
184. Li N, Nemirovskiy OV, Zhang Y, Yuan H, Mo J, et al. 2008. Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry. Anal. Biochem. 380:211-22
185. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, et al. 2012. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drugdrug interactions. J. Med. Chem. 55:4740-63
186. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, et al. 2012. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab. Dispos. 40:1007-17
187. Bi YA, Kimoto E, Sevidal S, Jones HM, Barton HA, et al. 2012. In vitro evaluation of hepatic transportermediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation. Drug Metab. Dispos. 40:1085-92
188. Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, et al. 2013. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin. Drug Metab. Toxicol. 9:459-72
189. Li M, Yuan H, Li N, Song G, Zheng Y, et al. 2008. Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. Eur. J. Pharm. Sci. 35:114-26
190. Li N, Singh P, Mandrell KM, Lai Y. 2010. Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. Mol. Pharm. 7:630-41
191. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311:139-46
192. Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, et al. 2007. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab. Dispos. 35:2166-76
193. Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K. 2009. Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion of metformin. Mol. Pharmacol. 75:1280-86
194. Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K. 2010. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 80:1762-67
195. Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. 2012. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab. Dispos. 40:1170-77
196. Wang W, Seward DJ, Li L, Boyer JL, Ballatori N. 2001. Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of a marine vertebrate. Proc. Natl. Acad. Sci. USA 98:9431-36
197. Seward DJ, Koh AS, Boyer JL, Ballatori N. 2003. Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTα- OSTβ. J. Biol. Chem. 278:27473-82
198. Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, et al. 2013. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin. Pharmacol. Ther. 94:126-41